March 20th 2023
Roger Li, MD, Moffit Cancer Center, was awarded the grant to study the novel oncolytic virus drug CG0070 in patients with intermediate-risk non–muscle-invasive bladder cancer.
Exploratory analysis shows no OS benefit with atezolizumab monotherapy in advanced urothelial cancerFebruary 18th 2023
An exploratory analysis of the IMvigor130 study failed to show an improvement in overall survival with atezolizumab, compared with placebo plus platinum-based chemotherapy and gemcitabine in patients with untreated locally advanced or metastatic urothelial cancer.
Tumor mutation burden may predict outcomes from ADC in urothelial carcinomaFebruary 17th 2023
The ORR for patients was 47%. Of note, ORRs were higher in patients with specific alterations compared with wild type including ERBB2 (67% vs. 44%, respectively; P = .05) and TSC1 (68% vs. 25%; P = .04).
Clinical complete response may guide eligibility for cystectomy in MIBCFebruary 17th 2023
In the the phase 2 HCRN GU 16-257 trial, 33 patients with muscle-invasive bladder cancer were eligible to forego cystectomy and continue 240-mg maintenance nivolumab monotherapy every 2 weeks for 8 cycles followed by surveillance.
Panel chair discusses latest updates to NCCN guidelines for bladder cancerFebruary 6th 2023
“A majority of patients that present with bladder cancer do not have muscle invasive disease. They have earlier stage, non-muscle invasive, and the NCCN guidelines have detailed guidance for providers about managing those patients,” said Thomas Flaig, MD.
iRARC adoption is slow but persistent in bladder cancerFebruary 1st 2023
"Over the past 10 to 15 years, tremendous efforts have gone into robotic surgical innovation to improve perioperative morbidity for patients with bladder cancer undergoing RC," write Andrew M. Wood, MD, and Nima Almassi, MD.
BCAN’s Young Investigator and Patient-Centered Clinical Research Awards are now openJanuary 23rd 2023
BCAN’s Young Investigator Awards support outstanding early-career scientists and clinical cancer researchers with a demonstrated commitment to improving the understanding and treatment of bladder cancer and/or upper tract urothelial cancer.
Trilaciclib regimen active in urothelial carcinoma but PFS data needed to determine true benefitJanuary 9th 2023
Adding trilaciclib to platinum-based chemotherapy and maintenance avelumab yielded responses in patients with untreated, locally advanced or metastatic urothelial carcinoma.